Hjem › Alvorlig depressiv lidelse › Missouri
Alvorlig depressiv lidelse kliniske forsøg i Missouri
16 studier for Alvorlig depressiv lidelse søger deltagere på steder i Missouri.
Byer i Missouri
Officiel studietekst (engelsk)
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Psychiatric Care and Research Center (PCRC), O'Fallon
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 25. sep. 2026 · NCT05850689Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Saint Charles
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 24. sep. 2026 · NCT06830044Lumateperone for Late-Life Depression
- Washington University School of Medicine, St Louis
RekruttererFase 3
Alder 60 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07623135A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, St Louis
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 14. sep. 2026 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- St. Charles Psychiatric Associates, Inc. dba Midwest Research Group, Saint Charles
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 14. sep. 2026 · NCT07284667A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Psychiatric Care and Research Center, O'Fallon
- St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles
RekruttererFase 3
Alder 18 til 74 · Alle køn · Opdateret 8. sep. 2026 · NCT07076407Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Washington University School of Medicine, St Louis
Rekrutterer
Alder 22 til 70 · Alle køn · Opdateret 28. aug. 2026 · NCT06423430A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Arch Clinical Trials, LLC, St Louis
RekruttererFase 3
Alder 18 til 74 · Alle køn · Opdateret 10. aug. 2026 · NCT07592689A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Arch Clinical Trials, St Louis
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 6. aug. 2026 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Tekton Research, St Louis
RekruttererFase 3
Alder 18 til 74 · Alle køn · Opdateret 3. aug. 2026 · NCT06775379A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, O'Fallon
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. jul. 2026 · NCT07196501Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, O'Fallon
- Neurocrine Clinical Site, Saint Charles
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. jul. 2026 · NCT06966401A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Midwest Research Group, Saint Charles
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 11. maj 2026 · NCT06524830NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
- Washington University School of Medicine, St Louis
RekruttererFase 1Frivillige med god helbredstilstand velkomne
Alder 18 til 65 · Alle køn · Opdateret 29. apr. 2026 · NCT02994433Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #127, Saint Charles
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 20. jan. 2026 · NCT06633016A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Saint Charles
RekruttererFase 4
Alder 18 til 65 · Alle køn · Opdateret 23. jan. 2025 · NCT06223880Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.